Renal Transplantation in Patients Older Than 60 Years With High Comorbidity. Is There a Survival Benefit? A Multicenter Study in Argentina.


Journal

Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144

Informations de publication

Date de publication:
08 2020
Historique:
entrez: 1 8 2020
pubmed: 1 8 2020
medline: 21 10 2020
Statut: ppublish

Résumé

The impact of renal transplantation (RT) in the elderly with many comorbid conditions is a matter of concern. The aim of our study was to assess the impact of RT on the survival of patients older than 60 years compared with those remaining on the waiting list (WL) according to their comorbidities. In this multicentric observational retrospective cohort study, we included all patients older than 60 years old admitted on the WL from 01 January 2006 to 31 December 2016. The Charlson comorbidity index (CCI) score was calculated for each patient at inclusion on the WL. Kidney donor risk index was used to assess donor characteristics. One thousand and thirty-six patients were included on the WL of which 371 (36%) received an RT during a median follow-up period of 2.5 (1.4-4.1) years. Patient survival was higher after RT compared to patients remaining on the WL, 87%, 80%, and 72% versus 87%, 55%, and 30% at 1, 3, and 5 years, respectively. After RT survival at 5 years was 37% higher for patients with CCI ≥ 3, and 46% higher in those with CCI < 3, compared with patients remaining on the WL. On univariate and multivariate analysis, patient survival was independently associated with a CCI of ≥3 (hazard ratio 1.62; confidence interval 1.09-2.41; P < 0.02) and the use of calcineurin-based therapy maintenance therapy (hazard ratio 0.53; confidence interval 0.34-0.82; P < 0.004). Our study showed that RT improved survival in patients older than 60 years even those with high comorbidities. The survival after transplantation was also affected by comorbidities.

Sections du résumé

BACKGROUND
The impact of renal transplantation (RT) in the elderly with many comorbid conditions is a matter of concern. The aim of our study was to assess the impact of RT on the survival of patients older than 60 years compared with those remaining on the waiting list (WL) according to their comorbidities.
METHODS
In this multicentric observational retrospective cohort study, we included all patients older than 60 years old admitted on the WL from 01 January 2006 to 31 December 2016. The Charlson comorbidity index (CCI) score was calculated for each patient at inclusion on the WL. Kidney donor risk index was used to assess donor characteristics.
RESULTS
One thousand and thirty-six patients were included on the WL of which 371 (36%) received an RT during a median follow-up period of 2.5 (1.4-4.1) years. Patient survival was higher after RT compared to patients remaining on the WL, 87%, 80%, and 72% versus 87%, 55%, and 30% at 1, 3, and 5 years, respectively. After RT survival at 5 years was 37% higher for patients with CCI ≥ 3, and 46% higher in those with CCI < 3, compared with patients remaining on the WL. On univariate and multivariate analysis, patient survival was independently associated with a CCI of ≥3 (hazard ratio 1.62; confidence interval 1.09-2.41; P < 0.02) and the use of calcineurin-based therapy maintenance therapy (hazard ratio 0.53; confidence interval 0.34-0.82; P < 0.004).
CONCLUSIONS
Our study showed that RT improved survival in patients older than 60 years even those with high comorbidities. The survival after transplantation was also affected by comorbidities.

Identifiants

pubmed: 32732855
doi: 10.1097/TP.0000000000003070
pii: 00007890-202008000-00037
doi:

Types de publication

Comparative Study Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1746-1751

Références

Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999; 341231725–1730
Tonelli M, Wiebe N, Knoll G, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011; 11102093–2109
Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int. 1996; 501235–242
Menzin J, Lines LM, Weiner DE, et al. A review of the costs and cost effectiveness of interventions in chronic kidney disease: implications for policy. Pharmacoeconomics. 2011; 2910839–861
Sistema Nacional de Información de procuración y Trasplante de la República Argentina (SINTRA).2018Available at https://cresi.incucai.gov.ar/IniciarCresiFromSintra.do. Accessed September 29, 2018
Kauffman HM, McBride MA, Cors CS, et al. Early mortality rates in older kidney recipients with comorbid risk factors. Transplantation. 2007; 834404–410
Meier-Kriesche HU, Cibrik DM, Ojo AO, et al. Interaction between donor and recipient age in determining the risk of chronic renal allograft failure. J Am Geriatr Soc. 2002; 50114–17
Hemmelgarn BR, Manns BJ, Quan H, et al. Adapting the Charlson comorbidity index for use in patients with ESRD. Am J Kidney Dis. 2003; 421125–132
Jassal SV, Schaubel DE, Fenton SS. Baseline comorbidity in kidney transplant recipients: a comparison of comorbidity indices. Am J Kidney Dis. 2005; 461136–142
Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 405373–383
KDPI calculatorOrgan Procurement and Transplantation Network.2018Available at https://optn.transplant.hrsa.gov/resources/allocation-calculators/kdpi-calculator/. Accessed June 23, 2018
Ojo AO, Hanson JA, Meier-Kriesche H, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol. 2001; 123589–597
Gill JS, Tonelli M, Johnson N, et al. The impact of waiting time and comorbid conditions on the survival benefit of kidney transplantation. Kidney Int. 2005; 6852345–2351
Bayat S, Kessler M, Briançon S, et al. Survival of transplanted and dialysed patients in a French region with focus on outcomes in the elderly. Nephrol Dial Transplant. 2010; 251292–300
Lloveras J, Arcos E, Comas J, et al. A paired survival analysis comparing hemodialysis and kidney transplantation from deceased elderly donors older than 65 years. Transplantation. 2015; 995991–996
Sørensen VR, Heaf J, Wehberg S, et al. Survival benefit in renal transplantation despite high comorbidity. Transplantation. 2016; 100102160–2167
Wu C, Shapiro R, Tan H, et al. Kidney transplantation in elderly people: the influence of recipient comorbidity and living kidney donors. J Am Geriatr Soc. 2008; 562231–238

Auteurs

Guillermo Daniel Fragale (GD)

Nefrología y Trasplante renal, Hospital Universitario Austral, Buenos Aires, Argentina.

Gervasio Soler Pujol (GS)

Sección Nefrología, Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno", Buenos Aires, Argentina.

Gustavo Laham (G)

Sección Nefrología, Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno", Buenos Aires, Argentina.

Pablo Raffaele (P)

Unidad renal, Fundación Favaloro, Buenos Aires, Argentina.

Marcela Fortunato (M)

Unidad renal, Fundación Favaloro, Buenos Aires, Argentina.

Nora Imperiali (N)

Trasplante renal, Hospital Italiano, Buenos Aires, Argentina.

María C Giordani (MC)

Trasplante renal, Hospital Italiano, Buenos Aires, Argentina.

Marcelo Taylor (M)

Centro Regional de Ablación e Implante Sur, Hospital San Martín, La Plata, Buenos Aires, Argentina.

Julio Ciappa (J)

Centro Regional de Ablación e Implante Sur, Hospital San Martín, La Plata, Buenos Aires, Argentina.

Natalia Matamala (N)

Nefrología y Trasplante renal, Clínica Vélez Sarsfield, Córdoba, Argentina.

Rafael Maldonado (R)

Nefrología y Trasplante renal, Clínica Vélez Sarsfield, Córdoba, Argentina.

Hernán Trimarchi (H)

Servicio de Nefrología, Hospital Británico, Buenos Aires, Argentina.

Vanesa Pomeranz (V)

Servicio de Nefrología, Hospital Británico, Buenos Aires, Argentina.

Sofia Naser (S)

Servicio de Nefrología, Hospital Privado Universitario de Córdoba, Argentina.

Jorge De La Fuente (J)

Servicio de Nefrología, Hospital Privado Universitario de Córdoba, Argentina.

Liliana Bisigniano (L)

Dirección Científico Técnica, Instituto Nacional Central Único Coordinador de Ablación e Implante (INCUCAI), Buenos Aires, Argentina.

Ariel Antik (A)

Dirección Científico Técnica, Instituto Nacional Central Único Coordinador de Ablación e Implante (INCUCAI), Buenos Aires, Argentina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH